A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.

Emma Dean, U Banerji, Romina Girotti, I Niculescu-Duvaz, F Lopes, L Davies, D Niculescu-Duvaz, N Dhomen, S Ellis, Z Ali, B O'Carrigan, L Carter, L Chisolm, Caroline Dive, HA Lane, Paul Lorigan, ME Gore, J Larkin, Richard Marais, C Springer

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Fingerprint

Dive into the research topics of 'A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science